Specialty Guideline Management

Zytiga (abiraterone)

POLICY

A. INDICATIONS
The indications below including FDA-approved indications and compendial uses are considered covered benefits provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication
• Zytiga is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.

All other indications are considered experimental/investigational and are not covered benefits.

B. CRITERIA FOR APPROVAL
1. Prostate Cancer
Authorization of 24 months may be granted to members prescribed Zytiga, in combination with prednisone, for the treatment of metastatic, castration-resistant prostate cancer.

C. CONTINUATION OF THERAPY
All members (including new members) requesting authorization for continuation of therapy must meet ALL initial authorization criteria.

D. DOSAGE AND ADMINISTRATION
Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

1. Dosing Limit
The following dosing limit applies:
• 1000 mg/day

REFERENCES